8 January 2019

No Price Control On New Drugs Patented In India



LexOrbis is a premier full-service IP law firm with 270 personnel including 130+ attorneys at its three offices in India namely, New Delhi, Bangalore and Mumbai. The firm provides business oriented and cost-effective solutions for protection, enforcement, transaction, and commercialization of all forms of intellectual property in India and globally. The Firm has been consistently ranked amongst the Top- 5 IP firms in India for over the past one decade and is well-known for managing global patent, designs and trademark portfolios of many technology companies and brand owners.
The new amendment in DPCO also exempts drugs for orphan diseases also known as orphan drugs from the price control mechanism.
India Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on

On January 3, 2019 the Government of India through the Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals) amended the Drugs (Price Control) Order, 2013 (DPCO) to exempt new patented drugs from price control for five years from the date of commencement of its commercial marketing by the manufacturer. The DPCO fixes the prices of scheduled formulations and monitors maximum retail prices of all drugs including the non-scheduled formulations sold in the country. Prior to the recent amendment in DPCO, exemption for five years was available to only those new drugs which were patented in India but were not produced elsewhere and were developed through indigenous research & development. Under the amended provisions of DPCO, any new drug can avail that exemption if it is patented in India under the provisions of Indian Patents Act, 1970 and developed and produced by the patentee anywhere in the world. The amended thus are likely to give impetus to "licensing in" of new drugs amongst the Indian drug manufacturers.

The new amendment in DPCO also exempts drugs for orphan diseases also known as orphan drugs from the price control mechanism. Orphan or rare diseases are uncommon disorders which are now receiving increasing attention of the researchers, the pharmaceutical industry and the government across the world but significant research on such diseases in India is still far behind. The number of orphan diseases however increasing and the list published by the US National Organization for Rare Disorders contains 1230 such diseases. The recent amendments made in the DPCO to exempt orphan drugs from the price control mechanism are aimed to incentives drug research in this field.

Another major change made by the recent amendment in DPCO is a shift from cost-based pricing to market-based pricing for fixing or revising the ceiling price for formulations by the Government. It was observed that the research on cost-based pricing was not robust and hence the market-based pricing was recommended. The recent amendments in DPCO were made on the recommendations of NITI AYOG and after completing the consultation process with the stakeholders.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More